Status: Recruiting
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Participants needed: 154
Trial details
Phase: Phase 3Age: 19+Biological sex: MaleType: InterventionalSponsor: Dongkook Pharmaceutical Co., Ltd.Updated: Jul 8, 2024Locations: 1
Eligibility criteria
Adult male aged 19 or older [+4]
History of surgical procedures such as testicular resection, adrenal resection,... [+21]